

Plant flavonoids as angiotensin converting enzyme inhibitors in regulation of hypertension

B.W. Nileeka Balasuriya and H.P. Vasantha Rupasinghe

Department of Environmental Sciences, Nova Scotia Agricultural College, PO Box 550, Truro, Nova Scotia B2N 5E3, Canada

Corresponding author: H.P. Vasantha Rupasinghe, PhD, Tree Fruit Bio-product Research Program, Department of Environmental Sciences, Nova Scotia Agricultural College, P.O. Box 550, Truro, Nova Scotia, Canada B2N 5E3

Submission date: March 6, 2011; Acceptance date: May 6, 2011; Publication date: May 8, 2011

Abstract

Background: Angiotensin converting enzyme (ACE) is a key component in the renin angiotensin aldosterone system (RAAS) which regulates blood pressure. As the over expression of RAAS is associated with vascular hypertension, ACE inhibition has become a major target control for hypertension. The research on potential ACE inhibitors is expanding broadly and most are focused on natural product derivatives such as peptides, polyphenolics, and terpenes. Plant polyphenolics are antioxidant molecules with various beneficial pharmacological properties. The current study is focused on investigating and reviewing the ACE inhibitory property of fruit flavonoids. An apple skin extract (ASE) rich in flavonoids, the major constituents of the extract and their selected metabolites were assessed for the ACE inhibitory property *in vitro*. It is important to investigate the metabolites along with the flavonoids as they are the constituents active inside the human body.

Objective: To investigate whether flavonoids, flavonoid rich apple extracts and their metabolites could inhibit ACE *in vitro*.

Method: The samples were incubated with sodium borate buffer (30 μ L, pH 8.3), 150 μ L of substrate (Hip-His-Liu) and ACE (30 μ L) at 37 °C for 1 h. The reaction was stopped by addition of 150 μ L of 0.3M NaOH. The enzyme cleaved substrate was detected by making a fluorimetric adduct by adding 100 μ L of o-phthalaldehyde for 10 min at room temperature. Reaction was stopped by adding 50 μ L of 3M HCl. Fluorescence was measured by using a FluoStar Optima plate reader at excitation of 350 nm and emission of 500 nm.

Results: The extract and the compounds showed a concentration dependant enzyme inhibition. Increasing concentrations from 0.001 ppm to 100 ppm of ASE showed an increment of 29% to 64% ACE inhibition. The IC₅₀ (concentration of test compound which gives 50% enzyme inhibition) values of ASE, quercetin, quercetin-3-glucoside, quercetin-3-galactoside, cyanidin-3-galactoside were 49 µg/mL, 151 µM, 71 µM, 180 µM, 206 µM, respectively. The major constituents of the ASE that were tested separately showed effective ACE inhibition. From the three metabolites tested, only quercetin-3-glucuronic acid showed concentration dependant ACE inhibition. The ACE inhibition of 0.001 ppm to 100 ppm of quercetin-3-glucuronic was in the range of 43% and 75% and the IC₅₀ value was 27 µM.

Conclusion: The results demonstrated that flavonoids have a potential to inhibit ACE *in vitro* and the inhibitory property varies according to type of sugar moiety attached at C-3 position. The results also revealed that the major contributing compounds of ASE for ACE inhibition belong to flavonoids. Among the tested compounds, the lowest IC₅₀ value is associated with the quercetin-3-glucuronic acid, a major *in vivo* metabolites of quercetin and its glycosides. The results suggest that certain dietary flavonoids may possess properties of blood pressure regulation.

Key words:

Hypertension, renin angiotensin system (RAS), angiotensin converting enzyme (ACE), flavonoids, apple

Background

Hypertension is a common progressive disorder leading to several chronic diseases such as cardiovascular disease, stroke, renal disease and diabetes. One-quarter of the world's adult population is afflicted by hypertension, and this is likely to increase to 29% by 2025 [1]. Life style changes, physical exercise, intake of healthy diets are some common issues associated with reducing the risk of hypertension. However, at critical stages drugs are essential. Therefore, it is of great importance to discover natural therapeutics for prevention and cure.

The pathogenesis of hypertension could be due to many reasons. For example, increased activity of renin angiotensin aldosterone system (RAAS), kalikerenin kinin system and sympathetic nervous system, and genetic influence are specified [2]. Among them over activation of RAAS (Fig. 1) is significant [3]. Angiotensin converting enzyme (ACE) plays a significant role in RAAS, by converting the precursor angiotensin I into angiotensin II which is the peptide responsible in triggering blood pressure increasing mechanisms. Therefore, inhibition of ACE is a promising way of controlling over expression of RAAS.

ACE inhibitory drugs are first class therapeutics since decades. Captopril[®], Lisinopril[®], Enalapril[®], and Ramipril[®] are some examples for drugs targeted as ACE inhibitors. However, the prolong use of the drugs could initiate adverse side effects like dizziness, coughing, and

angioneurotic edema [4]. New alternatives have been explored extensively as replacements of these drugs. Most of the researches have been targeted at bioactive compounds from natural resources. Peptides [5], anthocyanins [6], flavonols [7], triterpenes [8] are some examples. The objective of this review is to assess the potential of plant flavonoids to use as ACE inhibitors in regulation of hypertension.




Fig. 1: Renin angiotensin aldosterone system (RAAS)

ACE inhibition

ACE

ACE is a dipeptidyl carboxypeptidase with a zinc atom. The enzyme has a less substrate specificity *in vitro*. ACE consists of a single polypeptide chain containing two domains: N and C. There are two catalytic sites in each of these domains [9]. The highest concentrations of ACE are present in the lung capillaries. As well, ACE is present in renal proximal tubules, gastrointestinal tract, cardiac tissues and brain tissues [10]. It exists as a membrane bound enzyme as well as a circulatory or globular enzyme [9].

Assessment of Enzyme Inhibition

There are number of methods used in detection of ACE inhibition. Among them are spectrophotometric, fluorometric, high-performance liquid chromatographic (HPLC), radiochemical and electrophoresis methods [10, 11]. As there is less substrate specificity for ACE, several substrates have employed for *in vitro* enzyme inhibitory studies. Two commonly

used substrates for spectrophotometric and HPLC analysis of ACE inhibitory activity are hippuryl-L-histidyl-L-leucine (HHL) and N-(3-[2-furyl]acryloyl-phenylalanyl-glycyl-L-glycine (FAPGG) [12, 13]. HHL could be used in fluorescence detection methods of ACE inhibition along with fluorescing agents such as *o*-phthaldehyde [10]. The conversion of internally quenched fluorogenic substrates are reported to be very sensitive in detection of ACE inhibition. *o*-Aminobenzoylglycyl-p-nitro-phenylalanylproline [14] and abz-peptidyl-Eddnp (Abz: *ortho* amino benzoic acid. Eddnp: 2,4-dinitrophenyl ethylenediamine) are two examples of fluorogenic substrates [10].

Natural ACE Inhibitors

Different types of natural food derived compounds have been investigated on their ACE inhibitory properties. Food protein derivatives are a major group of compounds investigated as potential ACE inhibitors. Food proteins can be divided into three categories as animal-derived, plant-derived and microorganism-derived peptides. Animal-derived category includes peptides from milk, meat, fish and eggs [15]. Casein, whey protein hydrolysates from milk, ovokinin from eggs are reported to be effective ACE inhibitors in both *in vivo* and *in vitro* studies [15, 16]. Meat and fish proteins are hydrolyzed using different enzymes like chymases, and the resulting fractions are subjected in determining ACE inhibitory properties. Among the fish species used for deriving ACE inhibitory peptides are bonito, sardine, salmon, hake and tuna [17, 5]. Plant-derived peptides have also been identified from different sources including soybean, flaxseed, sunflower, rice, and corn [18, 19, 12]. There is less evidence on microorganism-derived peptides. Secondary metabolites produced in plants are another group of natural compounds which are identified as potential ACE inhibitors. Some terpenoids and polyphenolic compounds including flavonoids, hydrolysable tannins, xanthenes, procyanidins, caffeoylquinic acid derivatives are found to be effective as natural ACE inhibitors [20, 21]. Most studies have showed that plant extracts rich in phytochemicals found to be effective in ACE inhibition. However, identification of compounds specifically inhibit ACE is lacking in most of these investigations.

Flavonoids as ACE inhibitors

Flavonoids are the largest group of polyphenolic compounds found in higher plants [22]. Tea, wine, apples, onions, grapes, and oranges are some foods rich in flavonoids. The biosynthesis of flavonoids occurs in higher plants through the shikimic acid and malonic acid pathways [23]. The common structure of flavonoids is comprised of two phenyl rings (A and C rings) joined with three carbons which make a closed pyran ring structure (B ring) (Fig. 2) [24]. Based on the structural differences, flavonoids are further subdivided into six sub-groups namely flavanones, flavones, flavonols, flavan-3-ols, anthocyanins and isoflavones [24]. The highly diverse structures of flavonoids show numerous functions in biological systems. In plants, flavonoids contribute to: insect attraction and repulsion through colour of leaves, fruits and flowers; protection against viral, fungal and bacterial infections and UV light; nodulation in legume roots,

etc. [25]. Flavonoids are effective antioxidants in plants as well as in animals [22]. Flavonoids are identified as potential risk reducing components in the diet for cardiovascular disease, various cancers, neurodegenerative diseases, etc. [25]. For example, quercetin-3-*O*-glucoside, a flavonoid compound ubiquitous in fruits, has shown protective effect on human neuroblastoma cells (SH-SY5Y) against oxidative stress by a membrane injury recovery mechanism that is involved in up-regulation of genes involved in lipid and cholesterol synthesis [26].

The ability to use flavonoids as ACE inhibitors in regulating blood pressure had been studied during the past decades and most of them have proved to be effective in suppressing the activity of ACE [6, 7, 27]. The specificity of flavonoid sub-groups in inhibiting ACE would be discussed separately.

Anthocyanins

Anthocyanins are water soluble plant pigments giving rise to red, blue and purple colours of fruits and vegetables. In plants, they occur as anthocyanidins (aglycone form, Fig. 2) and then conjugate with sugars to form anthocyanins [24]. Anthocyanins have shown ACE inhibition *in vitro*. Delphinidin-3-*O*-sambubiosides and cyanidin-3-*O*-sambubiosides isolated from Hibiscus (*Hibiscus sabdariffa*) extracts had inhibited ACE in a dose dependant manner [6]. The IC₅₀ values of anthocyanins were found to be in 100 to 150 µM range (Table 1) [6]. Similarly, cyanidin-3-*O*-β-glucoside isolated from rose species (*Rosa damascene*) inhibited ACE *in vitro*. However, other flavonols isolated from rose extract were not effective ACE inhibitors when compared to cyanidin-3-*O*-β-glucoside [27]. Bilberry (*Vaccinium myrtillus*) extracts rich in major anthocyanins i.e. cyanidin, delphinidin and malvidin, were investigated on their effect on ACE in a human umbilical vein endothelial cell (HUVEC) culture model and the ACE activity had been significantly reduced after incubation of cells with bilberry extracts [28]. Dietary administration of anthocyanins-rich (cyanidin-3-glucosides, cyanidin-acyl-glucoside and peonidin-acyl-glucoside) purple corn, purple sweet potato and red radish to spontaneously hypertensive rats (SHR) had decreased the systolic and mean blood pressure [29]. The mechanisms behind the reduction of blood pressure by anthocyanins were reported due to their antioxidant activity, preservation of endothelial nitric oxide, and prevention of serum lipid oxidation but ACE inhibition was not found [29].

The observed ACE inhibitory activity of anthocyanins *in vitro* could be explained by the metal chelating ability of flavonoids with hydroxyl groups at 3, 5, 7 and 3', 4' positions [27, 28]. The planer structure of the anthocyanin molecules also indicated to be important in metallopeptidase inhibition [6]. In animals, the absorption rate and the corresponding metabolites of anthocyanins affect on the enzyme inhibition. However, a strong correlation between ACE inhibition *in vitro* and animal model systems has not been reported.

Flavan-3-ols (Flavanols)

Flavanols have a saturated C-ring with a hydroxyl group at the C-3 position (Fig. 2). They do not exist in glycosylated form as the other flavonoids. They can be found in both monomer form (catechins) and polymer form (procyanidins) [24]. When ACE was incubated with flavanol rich food extracts such as chocolates, tea and wine, a significant correlation between the ACE inhibition and the concentration of procyanidin and epicatechin was observed [30]. ACE inhibition by epicatechins of cocoa would be a reason for reported evidence for positive relationship between dark chocolate consumption and reduced high blood pressure [31]. The four major catechins, (-)-epicatechin, (-)-epigallocatechin, (-)-epicatechingallate and (-)-epigallocatechingallate, isolated from tea had also shown a dose dependant ACE inhibition in a HUVEC culture model [32]. Pycnogenol, a procyanidin oligomer, isolated from French maritime pine (*Pinus maritime*) had also reported as an effective mediator for blood pressure regulation possibly by ACE inhibition [33]. These studies prove that among flavonoids, flavanols and procyanidins could also act as potent inhibitors of ACE *in vitro*.

The relationship between structure of flavanols and ACE inhibitory properties *in vitro* had been studied [34]. Increasing numbers of epicatechin units in the procyanidins had increased the enzyme inhibition [34]. When tested using HUVEC cell cultures, tetramer was the most effective enzyme inhibitor compared to dimer and hexamer of procyanidins [34]. The monomers of flavanols were found to be absorbed in the small intestine [35]. However, absorption of procyanidins with higher molecular weight has not clearly been reported. Though the tetramers were proved to be the most effective *in vitro*, the dimers are more effective in biological systems compared to both tetramers and hexamers [34].

Flavonols

Flavonols (Fig. 2) are reported to be the most ubiquitous flavonoid sub-group present in foods. Quercetin, kaempferol and myricetin are the three types of most common flavonols in our diet [24]. ACE inhibitory property of many flavonols has been reported. When a bioassay-guided fractionation of extract of stonecrop (*Sedum sarmentosum*) was performed, five purified flavonols were found to possess ACE inhibitory activity [36] (Table 1). Kaempferol-rich stem bark extracts of Cluster Fig (*Ficus racemosa*) has shown a dose dependant ACE inhibition property *in vitro* [37]. Based on an *ex vivo* experiment conducted using aortic tissues of male Wistar-Kyoto rats, kaempferol was found to be an effective ACE inhibitor but not resveratrol [38], a polyphenolic that is abundant in red wine. The presence of carbonyl group in the pyran ring of kaempferol is lacking in resveratrol and this could be a reason for the differences in their ACE inhibitory activity. However, when strawberry extracts rich in flavonoids were tested for ACE inhibition *in vitro*, no ACE inhibition was observed [39]. Aqueous extracts of *Ginkgo biloba*, which had quercetin derivatives as the major flavonoids, had higher ACE inhibitory activity than that of ethanol extracts [40]. The aqueous extracts of red currents (*Ribes rubrum* L.) and black currents (*Ribes nigrum* L.) exhibited ACE inhibition *in vitro* but not the extracts of red and green gooseberries (*Ribes uva-crispa*) [41]. The variation of differences in ACE inhibitory

activity of plant extracts can be due to the presence of type of flavonoids and their concentration due to genetic differences of plant materials and the method of preparation of extracts, respectively.




Fig. 2: Basic structures of selected major flavonoids

Flavonols act as prominent antioxidants in biological systems. Dietary quercetin supplementation at 730 mg/d for 28 d was found to be effective in reducing blood pressure in hypertensive patients in a randomized, double-blind, placebo-controlled, crossover study [42]. In another study, Captopril[®] and quercetin treatments have been given to male Wistar rats separately, whose hypertensive responses were triggered by angiotensin I and bradykinin[®] injections. Bradykinin is a physiologically active peptide that causes blood vessels to enlarge. Both treatments triggered the hypotensive responses significantly and quercetin was equally effective to Captopril when given orally or intravenously [43]. Significant reduction of plasma ACE due to quercetin pretreatment (88.7 $\mu\text{mol/kg}$) was reported in this animal study. In contrast, chronic treatment of quercetin aglycone that was given at 10 mg/kg intraperitoneally for 14 ds to rats, did not inhibit plasma ACE activity with compared to the control group [44].

ACE is found to be involved in plasma protein extravasation (PE), which is an important component in neurogenic inflammation [45]. It is known that PE can be evoked by substance P which is hydrolyzed by ACE. Similar to the action of Captopril, dietary supplementation of quercetin can potentiate plasma PE induced by substance P in rat urinary bladder possibly by

inhibition of the peptidase which hydrolyze substance P [46]. From the reviewed literature, flavonols showed potential ACE inhibition both *in vitro* and *in vivo*. However, since flavonols are known to produce sulfate, glucuronide and methylated metabolites *in vivo* [47], ACE inhibition by quercetin metabolites *in vitro* required further investigation.

Isoflavones

Isoflavones are unique flavonoids as they exhibit structural similarity to mammalian estrogen hormone. They can effectively bind to the estrogen receptors and often called as phytoestrogens [48]. Genistein, daidzein and glycyetin are the common isoflavones present in plants ([24]. Among them, genistein is the prominent isoflavone widely investigated on health promoting effects. The major isoflavone in soybean is genistein [49]. Genistein has been reported for reducing blood pressure in animal models. For example, genistein has decreased NaCl-sensitive hypertension in stroke-prone spontaneously hypertensive rats [50]. Genistein dose-dependently decreased ACE gene expression and enzyme activity in rat aortic endothelial cells (RAEC). serum and aorta tissue [51]. However, the exact mechanisms for this modulation were not fully understood. Xu and co-workers (2006) found that genistein dose-dependently decreased ACE gene expression and enzyme activity in rat aortic endothelial cells (RAEC), serum and aorta tissue. The effect was mediated by estrogen receptor and subsequent activation of the ERK1/2 signaling pathway in RAEC. *In vitro* studies showed a concentration dependant ACE inhibition by genistein which was confirmed by others [52]. However, the presence of isoflavones in ACE inhibitory soybean peptide fractions had not shown any enhanced enzyme inhibitory effect when compared with the peptide fractions without isoflavones. Studies had conducted using animal models to investigate the *in vivo* activity of isoflavones. Pretreatment of single intravenous injection dose of genistein 25 mg/kg had shown reduced hypertensive responses in hypertensive Wistar rats. The reduced hypertension was associated with significant reduction of ACE activity in rat plasma [52]. Another *in vivo* study had proved that genistein can down regulate the ACE producing gene expression by interfering with cell signaling pathways [51]. However, there are no related studies on two other soybean isoflavones, daidzein and glycyetin, on ACE inhibitory effect.

Flavones

There is less information on ACE inhibitory properties of flavones when compared to the other types of flavonoids. However, extracts of Roxb (*Ailanthus excelsa*), Japanese cedar (*Cryptomeria japonica*), (*H. sabdariffa*) and *Senecio* species (Compositae) which comprise of flavones have shown the ACE inhibitory property [21, 53]. The two major flavones of Roxb, apigenin and luteolin, have shown a dose dependant enzyme inhibition. Compared to luteolin aglyconee, luteolin-7-*O*-glucoside had shown a reduced enzyme activity comprising to a higher IC₅₀ value (Table 1) [21]. The loss of hydroxyl group at 7th position could be the reason for the decreased enzyme inhibition by the glycoside. The ethanol extracts of the outer bark of Japanese

cedar has inhibited ACE *in vitro* and resulted an IC₅₀ value of 16 µg/mL. The extract was rich in flavan-3-ols and flavones. The enzyme inhibitory effect would be a result of the synergistic effect of all compounds present in the extract [54]. Crude hydroalcoholic extract rich in flavones from *H. sabdariffa* had shown satisfactory enzyme inhibition on ACE but not elastase, trypsin and alpha-chymotrypsin [55]. As all the studies discussed were investigating the effect of plant extracts containing flavones, the inhibitory effect could also be due to other constituents of the extract. Specific focus on isolated flavone compounds and their ACE inhibitory activity can generate valuable information about the flavones with ACE inhibition properties.

Other flavonoids

Chalcones are precursor molecules of the biosynthetic pathways of flavonoids [23]. These consist of two phenyl rings joined by a three carbon open chain. There are numerous evidences on beneficial pharmacological properties of chalcones. Chalcones and their pyrazole derivatives inhibited ACE in a concentration dependent manner *in vitro* [56]. Butein, a chalcone, supplementation through intravenous injection has been found to reduce the arterial blood pressure in anesthetized normotensive rats [20]. The ACE activities were found to be decreased in a dose dependant manner; however, the value of butein seems to be significantly greater than other flavonoids (Table 1).

Structurally modified flavonoids

In general, most of the phytochemicals including flavonoids are shown more effective beneficial pharmacological properties *in vitro* than *in vivo*. This could be due to several reasons including low bioavailability, lack of stability, poor membrane penetration, lack of site specific distribution and rapid elimination of these flavonoids [57]. Introducing structural modifications to flavonoids were found to be effective in enhancing some biological functionality of parent flavonoids. The methylated form of tea catechins had been found as effective ACE inhibitors. The methylated molecule epigallocatechin-3-*O*-(3-*O*-methyl)gallate had shown higher inhibition on ACE than epigallocatechin-3-*O*-gallate [58]. The results of the above mentioned study prove that structural modification of some flavonoids could offer a greater potential to use them as more effective ACE inhibitors.

Comparison of IC₅₀ Values of Flavonoids

The IC₅₀ values for ACE of most of reported flavonoids have summarized (Table 1). We have investigated the IC₅₀ values of quercetin, quercetin-3-glucoside, quercetin-3-galactoside and cyanidin-3-galactoside which were 151 µM, 71 µM, 180 µM, 206 µM, respectively (Balasuriya and Rupasinghe, unpublished). The values fall within the range of IC₅₀ values reported for other flavonoid compounds. Further we investigated the ACE inhibition of some selected flavonoid metabolites. Among the metabolites tested quercetin-3-glucuronic acid showed successful inhibition for ACE. Interestingly, the metabolite was the most effective when compared with all

other tested compounds, giving an IC₅₀ value of 27 μM. When compared to quercetin-3-glucoside, the presence of carboxylic acid group in the glucuronide, seems to contribute to the inhibition of ACE.

Some of the reported studies had focused on ACE inhibitory property of plant extracts. Table 2 summarizes the IC₅₀ values of effective plant extracts on ACE inhibition. In our study, a flavonoid-rich apple peel extract rich in flavonoids shows an IC₅₀ of 49 μM (Balasuriya and Rupasinghe, unpublished). Compared to other plant extracts reported, apple peel extract is an effective ACE inhibitor. When compared to all the reviewed flavonoid compounds, quercetin metabolites and plant extracts with the drugs (Table 3), none of the flavonoids or the extracts showed similar IC₅₀ values of the drugs. It is convincing that naturally occurring flavonoids are not potent treatments for hypertension but could offer promise for reducing the hypertension at early or mid stages of the risk.

Table 1: IC₅₀ values of ACE inhibitory flavonoids and their metabolites.

Group of Flavonoids	Compound	IC ₅₀ Value	Reference
Anthocyanins	Delphinidin-3- <i>O</i> -sambubioside	142 μM	[6]
	Cyanidin-3- <i>O</i> -sambubioside	118 μM	[6]
	Cyanidin-3- <i>O</i> -β-glucoside	139 μM	[27]
Flavones	Apigenin	280 μM	[21]
	Luteolin	290 μM	[21]
	Luteolin-7- <i>O</i> -glucopyranoside	280 μM	[21]
Flavonols	Quercetin glucuronide	200 μM	[60]
	Quercetin-3- <i>O</i> -(6''-galoyl)-galactoside	160 μM	[60]
	Quercetin-3- <i>O</i> -α-(6'''-caffeoylglucosyl-β-1,2-rhamnoside)	159 μM	[36]
	Quercetin-3- <i>O</i> -α-(6'''- <i>p</i> -coumaroylglucosyl-β-1,2-rhamnoside)	352 μM	[36]
	Isorhamnetin-3-β-glucopyranoside	409 μM	[36]
	Quercetin-3-β-glucopyranoside	709 μM	[36]
	Quercetin-3-α-arabinopyranoside	310 μM	[21]
	Kaempferol-3-α-arabinopyranoside	393 μM	[36]
Flavan-3-ols	Epicatechin - dimer	97 μM	[34]
	Epicatechin - tetramer	4 μM	[34]

	Epicatechin - hexamer	8 μ M	[34]
Chalcones	Butein	730 μ M	[20]
Flavonoid metabolites	Quercetin-3- <i>O</i> -glucuronic acid	27 μ M	Balasuriya and Rupasinghe (Unpublished)

Table 2: ACE inhibition (IC_{50} Values) by various plant extracts

Plant Extracts	IC_{50} Value	Reference
<i>Hibiscus sabdariffa</i> (Hibiscus)	91 μ g/mL	[6]
<i>Camelia synensis</i> (green tea)	125 μ g/mL	[61]
<i>Vaccinium ashei reade</i> (Blueberry leaf extract)	46 μ g/mL	[61]
<i>Vaccinium myrtillus</i> (Bilberry)	Log -2.6 mg/mL	[28]
<i>Senecio inaequidens</i> (A perennial herb)	192 μ g/mL	[53]
<i>S. ambiguous</i> subsp. <i>Ambigus</i> (ethyl acetate extract)	219 μ g/mL	[53]
<i>S. ambiguous</i> subsp. <i>Ambigus</i> (n-hexane extract)	307 μ g/mL	[53]
<i>Cryptomeria japonica</i> (Japanese Cedar)	16 μ g/mL	[54]
<i>Malus domestica</i> (Apple skin ethanol extract)	49 μ g/mL	Balasuriya and Rupasinghe (Unpublished)

Table 3: IC_{50} Values of ACE for Antihypertensive Drugs

Drug	IC_{50} Value	Reference
Captopril [®]	0.02 μ M	[36]
Lisinopril [®]	1.8 μ M	[6]

Enzyme Kinetic Studies

Some of the studies have focused on finding the type of enzyme inhibition of flavonoids. All compounds studied were in accordance with the Michaelis-Menten theorem. Anthocyanins have shown competitive type inhibition over ACE. Delphinidin-3-*O*-sambubioside, cyanidin-3-*O*-sambubioside, and anthocyanin rich fractions from *Hibiscus* species were among the samples

studied [6]. In a kinetic study conducted to find the effect of dimmers and tetramers of procyanidins at the presence of chloride ions on ACE had found a competitive type enzyme inhibition irrespective of the presence of chloride ions [34]. The dimmers and hexamers of the epicatechins were found to be competitive inhibitors. The inhibition over two types of substrates (HHL and FAPGG) was studied and no difference was observed depending on the substrate [7]. Most flavonoids were reported to be competitive type inhibitors meaning that they can compete with the substrate in binding to the active site of the enzyme. A group of condensed tannins (procyanidin B-5 3,3'-di-*O*-gallate and procyanidin C-1 3,3',3''-tri-*O*-gallate) isolated from *Rheirhizoma* had shown reversible and non competitive type of inhibition over ACE. The inhibitory kinetic were determined using Dixon plots [59]. There is not much evidence associated with the enzyme kinetics of specific flavonoids compared to other types of natural ACE inhibitors like plant and fish peptides. To the best of our knowledge, only flavan-3-ols and anthocyanins were the two flavonoid groups that were found to used for the enzyme kinetics studies.

Summary

Flavonoids are one of the major groups of plant secondary metabolites, with numerous beneficial pharmacological properties. Their recognition as effective biomolecules had made the scientists to investigate the potential use of flavonoids and flavonoid-rich extracts as natural ACE inhibitors, where the ACE activity is identified as a critical factor in regulating high blood pressure. All most all the subcategories of flavonoids were studied on ACE inhibitory activity. Though the IC_{50} values for ACE are very greater for flavonoids when compared with antihypertensive drugs, the most of the flavonoids are found to be competitive inhibitors of ACE.

Among flavonoids, flavan-3-ols and anthocyanins are effective ACE inhibitors *in vitro* as well as in animal model system. Catechins and their polymers proved to be the most effective ACE inhibitor *in vitro*. However, the results of the *in vitro* studies may not reflect exactly the outcome of *in vivo* studies. Therefore, further studies using animal models are required to confirm their ACE inhibitory properties. Isoflavones are showing intermediary inhibition towards ACE. Flavonols had proved to be less effective *in vitro* but in animal studies they were found to be more effective. Fewer studies had been conducted on flavones and chalcones. Structurally modified flavonoids designed for greater absorption and bioavailability could have a higher potential in use as ACE inhibitors. In terms of the mode of action, flavonoids had shown competitive type inhibition for ACE.

In conclusion, naturally occurring flavonoids have a potential to be used as mild or moderate ACE inhibitors. As the IC_{50} values of flavonoids were higher than that of the prescribed drugs for hypertension, flavonoids could be used as preventative nutraceuticals over hypertension rather than using as therapeutic drug for hypertension. Flavonoid-derived natural health products could become popular among patients with mild hypertension as well as the patients who have adverse side effects for currently available antihypertensive drugs. Future

research should also be focused on structural modifications of flavonoids and their antihypertensive properties.

Abbreviations: Angiotensin converting enzyme (ACE), Hippuryl-L-histidyl-L-leucine (HHL), N-(3-[2-furyl]acryloyl-phenylalanyl-glycyl-L-glycine (FAPGG), High performance liquid chromatography (HPLC)

Authors' contributions

H.P. Vasantha Rupasinghe, PhD. is the principle investigator for this study providing oversight and contributed fundamental conceptualization for the research. E-mail: vrupasinghe@nsac.ca

B.W. Nileeka Balasuriya, M.Sc. is a graduate student who has performed all of the experiments reported in this manuscript. E-mail: nbalasuriya@nsac.ca.

Acknowledgement and Funding

The financial support for this study was provided by the Discovery Grant program of the Natural Science and Engineering Research Council (NSERC) of Canada. The authors would like to greatly acknowledge the generous supply of quercetin metabolites for this study by Dr. Paul Kroon of the Institute of Food Research, Norwich Research Park, Colney, Norwich, UK.

References

1. Mittal BV, Singh AK. Hypertension in the developing world: challenges and opportunities. *Am J Kidney Dis* 2010; 55(3):590-8.
2. Oparil MD, Zaman MA, Calhoun DA. Pathogenesis of hypertension. *Ann Intern Med* 2003; 139:761-76.
3. Hammoud RA, Vaccari CS, Nagamia SH, Khan BV. Regulation of the renin-angiotensin system in coronary atherosclerosis: a review of the literature. *Vasc Health Risk Manag* 2007; 3(6):937-45.
4. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. *Ann Intern Med* 1992; 117(3):234-42.
5. Cinq-Mars CD, Li-Chan ECY. Optimizing angiotensin 1-converting enzyme inhibitory activity of Pacific Hake (*Merluccius productus*) fillet hydrolysate using response surface methodology and ultrafiltration. *J Agric Food Chem* 2007; 55(23):9380-8.
6. Ojeda D, Jiménez-Ferrer E, Zamilpa A, Herrera-Arellano A, Tortoriello J, Alvarez L. Inhibition of angiotensin converting enzyme (ACE) activity by the anthocyanins delphinidin- and cyanidin-3-O-sambubiosides from *Hibiscus sabdariffa*. *J Ethnopharmacol* 2010; 127(1):7-10.
7. Actis-Goretta L, Ottaviani JI, Keen CL, Fraga CG. Inhibition of angiotensin converting enzyme (ACE) activity by flavan-3-ols and procyanidins. *FEBS Lett* 2003; 555(3):597-600.

8. Somova LO, Nadar A, Rammanan P, Shode FO. Cardiovascular, antihyperlipidemic and antioxidant effects of oleanolic and ursolic acids in experimental hypertension. *Phytomedicine* 2003; 10(2-3):115-21.
9. Ortiz-Salmerón E, Barón C, García-Fuentes L. Enthalpy of captopril-angiotensin I-converting enzyme binding. *FEBBS Lett* 1998; 435(2-3):219-24.
10. Alves MF, Arajujo MC, Juliano MA, Oliveira EM, Krieger JE, Casarini DE, Juliano L, Carmona AK. A continuous florescent assay for the determination of plasma and tissue angiotensin I converting enzyme activity. *Braz J Med Biol Res* 2005; 38(6):861-8.
11. Lahogue V, Réhel K, Taupin L, Haras D, Allauame P. A HPLC-UV method for the determination of angiotensin I-converting enzyme (ACE) inhibitory activity. *Food Chem* 2010; 118(3):870-5.
12. Udenigwe CC, Lin YS, Hou WC, Aluko RE. Kinetics of the inhibition of renin and angiotensin I-converting enzyme by flaxseed protein hydrolysate fractions. *J Func Foods* 2009.1(2):199-207.
13. Wu J, Aluko RE, Muir AD. Purification of angiotensin I-converting enzyme peptides from the enzymatic hydrolysate of defatted canola meal. *Food Chem* 2008; 111(4):942-50.
14. Sentandreu MA, Toldrá F. A rapid, simple and sensitive fluorescence method for the assay of angiotensin-I converting enzyme. *Food Chem* 2006; 97:546-54.
15. Hong F, Ming L, Yi S, Zhanxia L, Yongquan W, Chi L. The antihypertensive effect of peptides: A novel alternative to drugs? *Peptides* 2008; 29(6):1062-71.
16. Yamamoto N. Antihypertensive peptides derived from food proteins. *Biopolymers* 1997; 43(2):129-34.
17. Vercruyse L, Camp JV, Smagghe G. ACE inhibitory peptides derived from enzymatic hydrolysates of animal muscle protein: a review. *J Agric Food Chem* 2005; 53(21):8106-15.
18. Farzamirad V, Aluko RE. Angiotensin-converting enzyme inhibition and free-radical scavenging properties of cationic peptides derived from soybean protein hydrolysates. *Int J Food Sci Nutr* 2008; 59(5) 428-37.
19. Guang C, Phillips RD. Plant food-derived angiotensin I converting enzyme inhibitory peptides. *J Agric Food Chem* 2009; 57(12):5113-20.
20. Kang DG, Kim YC, Sohn EJ, Lee YM, Lee AS, Yin MH, Lee HS. Hypotensive effect of butein via inhibition of angiotensin converting enzyme. *Biol Pharm Bull* 2003; 26(9):1345-7.
21. Loizzo MR, Said A, Tundis R, Rashed K, Statti GA, Hufner A, Menichini F. Inhibition of angiotensin converting enzyme (ACE) by flavonoids isolated from *Ailanthus excels* (Roxb) (Simaroubaceae). *Phytother Res* 2007; 21:32-6.
22. Croft KD. The chemistry and biological effects of flavonoids and phenolic acids. *Ann N Y Acad Sci* 1998; 854:435-42.
23. Rupasinghe HPV. The role of polyphenols in quality, postharvest handling and processing of fruits. Ed: Paliyath G, Lurie S, Murr D. Handa A. *Postharvest Biology and Technology of Fruits, Vegetables, and Flowers*. Wiley-Blackwell Publishers. 2008; pp 260-81.
24. D'Archivio M, Filesi C, Benedetto RD, Gargiulo R, Giovannini C, Masella R. Polyphenols, dietary sources and bioavailability. *Ann 1st Super Sanita* 2007; 43(4):348-61.

25. Stevenson DE, Hurst RD. Polyphenolic phytochemicals -- just antioxidants or much more? *Cell Mol Life Sci* 2007; 64(22):2900-16.
26. Soundararajan R, Wishart AD, Rupasinghe HPV, Arcellena-Panlilio M, Nelson CM, Mayne M, Robertson GS. Quercetin 3-glucoside protects neuroblastoma (SH-SY5Y) cells *in vitro* against oxidative damage by inducing sterol regulatory element-binding protein-2-mediated cholesterol biosynthesis. *J Biol Chem* 2008; 284(4):2231-45.
27. Kwon EK, Lee DY, Lee H, Kim DO, Baek NI, Kim YE, Kim HY. Flavonoids from the buds of *Rosa damascena* inhibit the activity of 3-hydroxy-3-methylglutaryl-coenzyme a reductase and angiotensin I-converting enzyme. *J Agric Food Chem* 2010; 58(2):882-6.
28. Persson IAL, Persson K, Andersson RGG. Effect of *Vaccinium myrtillus* and its polyphenols on angiotensin-converting enzyme activity in human endothelial cells. *J Agric Food Chem* 2009; 57(11):4626-29.
29. Shindo M, Kasai T, Abe A, Konido Y. Effects of dietary administration of plant-derived anthocyanin-rich colours to spontaneously hypertensive rats. *J Nutr Sci Vitaminol* 2007; 53(1):90-3.
30. Actis-Goretta L, Ottaviani JI, Fraga CG. Inhibition of angiotensin converting enzyme activity by flavanol-rich foods. *J Agric Food Chem* 2006; 54(1):229-34.
31. Egan BM, Laken MA, Donovan JL, Woolson RF. Does dark chocolate have a role in the prevention and management of hypertension? Commentary on the evidence. *Hypertension* 2010; 55:1289-95.
32. Persson IA, Joseffsson M, Persson K, Anderson RG. Tea flavanols inhibit angiotensin-converting enzyme activity and increase nitric oxide production in human endothelial cells. *J Pharm Pharmacol* 2006; 58(8):1139-44.
33. Zibadi S, Rohdewald PJ, Park D, Watson RR. Reduction of cardiovascular risk factors in subjects with type 2 diabetes by Pycongenol supplementation. *Nutr Res* 2008; 28:315-20.
34. Ottaviani JI, Actis-Goretta L, Villordo JJ, Fraga CG. Procyanidin structure defines the extent and specificity of angiotensin I converting enzyme inhibition. *Biochimie* 2006; 88:359-65.
35. García-Cornesa MT, Tribolo S, Guyot S, Tomás-Barberán FA, Kroon PA. Oligomeric procyanidins inhibit cell migration and modulate the expression of migration and proliferation associated genes in human umbilical vascular endothelial cells. *Mol Nutr Food Res* 2009; 53(2):266-76.
36. Oh H, Kang DG, Kwon JW, Kwon TO, Lee SY, Lee DB, Lee HB. Isolation of angiotensin converting enzyme (ACE) inhibitory flavonoids from *Sedum sarmentosum*. *Biol Pharm Bull* 2004; 27:2035-7.
37. Ahmed F, Siddesha JM, Urooj A, Vishwanath BS. Radical scavenging and angiotensin converting enzyme inhibitory activities of standardized extracts of *Ficus racemosa* stem bark. *Phytother Res* 2010; 24(12):1839-43.

38. Olszanecki R, Bujak-Gizycka B, Madej J, Suski M, Wolkow PP, Jawi n J, Korbut R. Kaempferol, but not resveratrol inhibits angiotensin converting enzyme. *J Physiol Pharmacol* 2008; 59:(2)387-92.
39. Pinto MD-S, Kwon YI, Apostolidis E, Lajolo FM, Genovese MI, Shetty K. Functionality of bioactive compounds in Brazilian strawberry (*Fragaria x ananassa* Duch.) cultivars: evaluation of hyperglycemia and hypertension potential using *in vitro* models. *J Agric Food Chem* 2008; 56(12):4386-92.
40. Pinto MD-S, Kwon YI, Apostolidis E, Lajolo FM, Genovese MI, Shetty K. Potential of *Ginkgo biloba* L. leaves in the management of hyperglycemia and hypertension using *in vitro* models. *Bioresource Technol* 2009; 100(24):6599-6609.
41. Pinto MD-S, Kwon YI, Apostolidis E, Lajolo FM, Genovese MI, Shetty K. Evaluation of red currants (*Ribes rubrum* L.) black currents (*Ribes nigrum* L.) red and green gooseberries (*Ribes uva-crisp* A) for potential management of type 2 diabetes and hypertension using *in vitro* models. *J Food Biochem* 2010; 34:639-60.
42. Edwards RL, Lyon T, Litwin SE, Rabovsky A, Symons JD, Jalili T. Quercetin reduces blood pressure in hypertensive subjects. *J Nutr* 2007; 137:2405-11.
43. H ckl LPN, Cuttle G, Dovichi SS, Lima-Landman MT, Nicolau M. Inhibition of angiotensin converting enzyme by quercetin alters the vascular response to bradykinin and angiotensin I. *Pharmacol* 2002; 65:182-6.
44. Neto-Neves EM, Montenegro MF, Dias-Junior CA, Spiller F, Kanashiro A, Tanus-Santos JE. Chronic treatment with quercetin does not inhibit angiotensin-converting enzyme *in vivo* or *in vitro*. *Basic Clin Pharmacol Toxicol* 2010; 107(4):825-9.
45. Wille PR, Ribeiro-do-Valle RM, Sim es CMO, Gabilan NH, Nicalou M. Effect of quercetin on tachykinin-induced plasma extravasation in rat urinary bladder. *Phytother Res* 2001; 15(5):444-6.
46. Nicolau M, Dovichi SS, Cuttle G. Pro-inflammatory effect of quercetin by dual blockade of angiotensin converting-enzyme and neutral endopeptidase *in vivo*. *Nutr Neurosci* 2003; 6(5):309-16.
47. Rupasinghe HPV, Ronalds CM, Rathgeber B, Robinson RA. Absorption and tissue distribution of dietary quercetin and quercetin glycosides of apple skin in broiler chickens. *J Sci Food Agric* 2010; 90(7):1172-8.
48. Jackson CJC, Rupasinghe HPV. Food sources and composition of phytoestrogens. In: *Phytoestrogens and Health* (Ed.) Messina M, AOCS Press, Champaign, IL, USA. 2002; pp. 95-123.
49. Wu J, Muir AD. Isoflavone content and its potential contribution to the antihypertensive activity in soybean angiotensin I converting enzyme inhibitory peptides. *J Agric Food Chem* 2008; 56(21):9899-904.

50. Cho TM, Peng N, Clark JT, Novak L, Roysommuti S, Prasain J, Wyss JM. Genistein attenuates the hypertensive effects of dietary NaCl in hypertensive male rats. *Endocrinology* 2007; 148(11):5396-402.
51. Xu YY, Yang C, Li SN. Effects of genistein on angiotensin-converting enzyme in rats. *Life Sci* 2006; 79(9):828-37.
52. Montenegro MF, Pessa LR, Tanus-Santos JE. Isoflavone genistein inhibits the angiotensin converting enzyme and alters the vascular responses to angiotensin I and bradykinin. *Eur J Pharmacol* 2009; 607(1-3):173-177.
53. Loizzo MR, Tundis R, Conforti F, Statti GA, Menichini F. Inhibition of angiotensin converting enzyme activity by *Senecio* Species. *Pharm Biol* 2009; 47(6):516-20.
54. Tsutsumi Y, Shimada A, Miyano A, Nishida T, Mitsunaga T. *In vitro* screening of angiotensin I-converting enzyme inhibitors from Japanese cedar (*Crptomera japonica*). *J Wood Sci* 1997; 44(6):463-8.
55. Jonadet M, Bastide J, Bastide P, Boyer B, Carnat AP, Lamaison JL. *In vitro* enzyme inhibitory and *in vivo* cardioprotective activities of hibiscus (*Hibiscus sabdariffa L.*). *J Pharm Belg* 1990; 45(2):120-4.
56. Bonsei M, Loizzo MR, Statti GA, Michel S, Tillequin F. The synthesis and angiotensin converting enzyme (ACE) inhibitory activity of chalcones and their pyrazole derivatives. *Bioorg Medicinal Chem Lett* 2010; 20(6):1990-3.
57. Srinivas NR. Structurally modified 'dietary flavonoids': are these viable drug candidates for chemoprevention? *Curr Clin Phamacol* 2009; 4(1):67-70.
58. Kurita I, Yamamoto MM, Tachibanas H, Kamei M. Antihypertensive effect of Benifuuki tea containing O-methylated EGCG. *J Agric Food Chem* 2010; 58(3):1903-8.
59. Uchida S, Ikari N, Ohta M, Niwa M, Nonaka G, Nishioka I, Ozaki M. Inhibitory effects of condensed tannins on angiotensin converting enzyme. *Jpn J Phamacol* 1987; 43(2):242-6.
60. Kiss A, Kowalski J, Melzig MF. Compounds from *Epilobium angustifolium* inhibit the specific metallopeptidases ACE, NEP, and APN. *Planta Med* 2004; 70(10):919-23.
61. Sakaida H, Nagao K, Higa K, Shirouchi B, Inoue N, Hidaka F, Kai T, Yanagita T. Effect of *Vaccinium ashei reade* leaves on angiotensin converting enzyme activity *in vitro* and systolic blood pressure of spontaneously hypertensive rats *in vivo*. *Biosci Biotechnol Biochem* 2007; 71(9):2335-7